• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mast Therapeutics inks deal with Philips Respironics for iNeb aerosol delivery device

October 17, 2016 By Sarah Faulkner

Mast Therapeutics, Philips RespironicsMast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals landed a collaborative agreement with Royal Philips (NYSE:PHG) sleep and respiratory care subsidiary Philips Respironics. The agreement covers Philips’ iNeb aerosol drug delivery device and Mast’s lead product candidate, AIR001, a sodium nitrite solution for intermittent inhalation.

The iNeb system is a portable, small vibrating mesh technology nebulizer that is delivers more reproducible doses of medication faster than ultrasonic nebulizers, according to Philips.

San Diego, Calif.-based Mast has 2 clinical stage investigational drugs, including AIR001, which is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction. In early clinical studies of AIR001, according to Mast, researchers observed positive hemodynamic effects with reductions observed in right atrial pressure and pulmonary capillary wedge pressure. They also saw improvements in pulmonary artery pressure, cardiac output, and exercise tolerance.

“As we announced last month, we are accelerating activities related to our AIR001 program with support for ongoing, investigator-sponsored phase II clinical studies of AIR001 being conducted at 3 separate prestigious research institutions,” CEO Brian Culley said in prepared remarks. “As part of this commitment, we are pleased to be working with Philips, a recognized global leader in the development of aerosol delivery devices and a leading provider of innovative solutions for the global respiratory market. Our agreement has been extended to include not only 2 of the phase II studies of AIR001 currently underway, but also future clinical studies and will remain in place until 2020 or sooner, if replaced with a commercial supply agreement.”

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Research & Development Tagged With: Mast Therapeutics, Royal Philips

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS